| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |